BMY Form 4: Director holdings rise to 10,076.278 shares after 776 DSUs
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Michael R. McMullen, a director of Bristol-Myers Squibb Company (BMY), reported an acquisition on 09/30/2025 of 776.053 Deferred Share Units. Each Deferred Share Unit will convert into one share of common stock upon settlement, and the units become settleable when the reporting person ceases to be a director or at a previously specified future date. Following this transaction and prior deferred holdings, the filing shows the reporting person beneficially owns 10,076.278 shares (direct). The Form 4 was filed by an attorney-in-fact and signed on behalf of Mr. McMullen on 10/02/2025.
Positive
- Acquired 776.053 Deferred Share Units on 09/30/2025
- Beneficial ownership increased to 10,076.278 shares (direct)
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
McMullen Michael R.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Share Units | 776.053 | $0.00 | -- |
Holdings After Transaction:
Deferred Share Units — 10,076.278 shares (Direct)
Footnotes (1)
- Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
FAQ
What did Michael R. McMullen report on the BMY Form 4?
He reported acquiring 776.053 Deferred Share Units on 09/30/2025, which convert to common shares upon settlement.
Who signed the Form 4 for Michael R. McMullen and when?
The Form was signed by Sophie M. Bail, attorney-in-fact for Michael R. McMullen, on 10/02/2025.